Akero Therapeutics to Present at the Jefferies London Healthcare Conference
Akero Therapeutics (Nasdaq: AKRO) has announced its upcoming participation in the Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 19, 2024, at 12:00 p.m. GMT. Akero, which focuses on developing treatments for serious metabolic diseases, will make the presentation available via live webcast through their investor relations website. An archived replay will be accessible on www.akerotx.com following the live event.
Akero Therapeutics (Nasdaq: AKRO) ha annunciato la sua prossima partecipazione alla Jefferies London Healthcare Conference. Il management dell'azienda parteciperà a una chiacchierata informale martedì 19 novembre 2024, alle 12:00 GMT. Akero, che si concentra sullo sviluppo di trattamenti per gravi malattie metaboliche, renderà la presentazione disponibile tramite webcast dal vivo sul loro sito web per le relazioni con gli investitori. Una registrazione archiviata sarà accessibile su www.akerotx.com dopo l'evento dal vivo.
Akero Therapeutics (Nasdaq: AKRO) ha anunciado su próxima participación en la Jefferies London Healthcare Conference. La dirección de la compañía participará en una charla informal el martes 19 de noviembre de 2024, a las 12:00 p.m. GMT. Akero, que se centra en el desarrollo de tratamientos para enfermedades metabólicas graves, hará que la presentación esté disponible a través de una transmisión en vivo en su sitio web de relaciones con inversores. Una repetición archivada estará accesible en www.akerotx.com tras el evento en vivo.
Akero Therapeutics (Nasdaq: AKRO)는 Jefferies London Healthcare Conference에 참여할 예정임을 발표했습니다. 회사 경영진은 2024년 11월 19일 화요일 GMT 기준 오후 12시에 진행되는 화상 대화에 참여할 것입니다. Akero는 심각한 대사 질환에 대한 치료제를 개발하는 데 중점을 두며, 발표는 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 제공될 예정입니다. 실시간 이벤트 이후 www.akerotx.com에서 아카이브된 다시보기가 가능합니다.
Akero Therapeutics (Nasdaq: AKRO) a annoncé sa prochaine participation à la Jefferies London Healthcare Conference. La direction de l'entreprise participera à une discussion informelle le mardi 19 novembre 2024 à 12h00 GMT. Akero, qui se concentre sur le développement de traitements pour des maladies métaboliques graves, rendra la présentation disponible via un webinaire en direct sur son site de relations investisseurs. Un replay archivé sera accessible sur www.akerotx.com après l'événement en direct.
Akero Therapeutics (Nasdaq: AKRO) hat seine kommende Teilnahme an der Jefferies London Healthcare Conference bekannt gegeben. Das Management des Unternehmens wird am Dienstag, den 19. November 2024, um 12:00 Uhr GMT an einem informellen Gespräch teilnehmen. Akero, das sich auf die Entwicklung von Therapien für schwere Stoffwechselerkrankungen konzentriert, wird die Präsentation über einen Live-Webcast auf seiner Investor-Relations-Website verfügbar machen. Eine aufgezeichnete Wiederholung wird nach der Live-Veranstaltung auf www.akerotx.com zugänglich sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH (F2-F3) or compensated cirrhosis (F4) due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the completed HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the ongoing SYMMETRY study in patients with compensated cirrhosis (F4) due to MASH, in which more than 300 patients have been treated for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com
FAQ
When is Akero Therapeutics (AKRO) presenting at the Jefferies London Healthcare Conference 2024?
How can I watch Akero Therapeutics' (AKRO) presentation at the Jefferies Conference?
What type of presentation will Akero Therapeutics (AKRO) give at the Jefferies London Healthcare Conference?
What is the focus area of Akero Therapeutics (AKRO)?
